🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 23 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/09/2019 7,57 7,91 7,45 7,80 +4,56% 6,08% 72.000
04/09/2019 7,37 7,66 7,37 7,46 +1,36% 3,93% 79.800
03/09/2019 7,73 7,94 7,19 7,36 -5,76% 9,70% 93.500
30/08/2019 7,29 8,15 7,28 7,81 +6,55% 11,93% 174.200
29/08/2019 6,87 7,42 6,83 7,33 +8,43% 8,59% 116.700
28/08/2019 6,69 6,96 6,69 6,76 +1,05% 4,04% 109.400
27/08/2019 6,78 6,85 6,54 6,69 +0,30% 4,57% 330.500
26/08/2019 6,54 6,78 6,42 6,67 +3,57% 5,50% 121.200
23/08/2019 6,75 6,91 6,36 6,44 -5,29% 8,15% 121.800
22/08/2019 7,00 7,05 6,72 6,80 -2,58% 4,71% 67.400
21/08/2019 7,23 7,25 6,97 6,98 -1,97% 3,87% 255.800
20/08/2019 7,21 7,28 6,95 7,12 -1,39% 4,65% 70.200
19/08/2019 7,51 7,51 7,14 7,22 -2,17% 4,93% 313.500
16/08/2019 7,15 7,60 7,08 7,38 +3,80% 7,27% 157.900
15/08/2019 7,01 7,25 6,84 7,11 +1,57% 5,85% 70.900
14/08/2019 7,30 7,46 6,98 7,00 -5,41% 6,58% 154.700
13/08/2019 7,19 7,56 7,19 7,40 +4,23% 5,15% 69.500
12/08/2019 7,09 7,58 7,04 7,10 -2,47% 7,62% 218.000
09/08/2019 7,57 7,72 7,26 7,28 -2,41% 6,05% 168.700
08/08/2019 6,91 7,56 6,89 7,46 +11,01% 9,70% 307.100
07/08/2019 6,78 7,10 6,32 6,72 -0,44% 11,50% 448.100
06/08/2019 6,64 6,96 6,52 6,75 +2,27% 6,63% 137.700
05/08/2019 6,74 6,74 6,30 6,60 -3,51% 6,53% 279.300
02/08/2019 7,26 7,35 6,72 6,84 -6,81% 8,68% 129.500
01/08/2019 7,91 8,06 7,25 7,34 -7,21% 10,24% 138.300
31/07/2019 8,00 8,47 7,89 7,91 -1,13% 7,25% 162.400
30/07/2019 7,99 8,33 7,95 8,00 -0,62% 4,72% 104.200
29/07/2019 8,40 8,49 7,99 8,05 -4,39% 5,95% 70.400
26/07/2019 8,39 8,47 8,16 8,42 +1,57% 3,68% 42.400
25/07/2019 8,64 8,64 8,24 8,29 -4,38% 4,63% 35.700